Home
 

Pharmacy Benefits Management

 
May 13, 2015 | Anthony Brino

$52 billion and growing is the trend in high-cost pharmacy benefits, as more and more Americans use prescription drugs with expenses exceeding the U.S. median household income.


May 12, 2015 | Phil Galewitz, Kaiser Health News

When it comes to comprehensive contraception options as a preventive health benefit, free means free, regulators reminded the insurance industry.


May 1, 2015 | Anthony Brino

If the time for precision medicine is now, could the massive databases of health and drug plan claims systems be a starting point?


April 17, 2015 | Anthony Brino

What constitutes reasonable limitations and management of contraception as an essential preventive health benefit? In the wake of new data and some consumer complaints, HHS may try to resolve gray areas.


April 14, 2015 | Anthony Brino

A fresh stream of data is raising some concerns about a new class of diabetes medicines and their relation to long-term heart health.


April 3, 2015 | Anthony Brino

A lot of health insurers still have many miles to go on the road to parity for consumers seeking mental health and substance abuse treatment, patient advocates maintain.


March 31, 2015 | Anthony Brino

Are exchange insurers failing to adequately cover mandated tobacco cessation at no cost-sharing, or just not explicitly highlighting the benefits?


March 30, 2015 | Anthony Brino

America's largest insurer is looking for all the scale it can get in the war for affordable medicines.


March 12, 2015 | Anthony Brino

Health insurers and American consumers might be spending more than ever for prescription drugs, but there are also more choices and more information to find value in a sea of volume.


March 9, 2015 | Anthony Brino

An increasingly popular strategy in drug plan affordability is again coming under scrutiny from Medicare regulators concerned that some urban seniors are being left out.


March 6, 2015 | Anthony Brino

Health insurers and patients could get a bit of relief after years of paying more and more for biologic speciality pharmaceuticals, but some think there are still barriers to affordability.


March 4, 2015 | Anthony Brino

Middle-age American men have been aggressively marketed treatments for low testosterone, despite risks and skepticism about benefits. Now insurers have another reason to strictly control coverage.


Advertisement. Closing in 15 seconds.